DrugCentral 2021 supports drug discovery and repositioning

Sorin Avram1,†, Cristian G. Bologa2,3,†, Jayme Holmes2, Giovanni Bocci2, Thomas B. Wilson4, Dac-Trung Nguyen5, Ramona Curpan1, Liliana Halip1, Alina Bora1, Jeremy J. Yang2, Jeffrey Knockel6, Suman Sirimulla7, Oleg Ursu8 and Tudor I. Oprea2,8,9,10,*

1Department of Computational Chemistry, “Coriolan Dragulescu” Institute of Chemistry, 24 Mihai Viteazu Blvd, Timișoara, Timiș, 300223, România, 2Translational Informatics Division, Department of Internal Medicine, University of New Mexico Health Sciences Center, Albuquerque, NM 87131, USA, 3UNM Comprehensive Cancer Center, University of New Mexico Health Sciences Center, Albuquerque, NM 87131, USA, 4College of Pharmacy, University of New Mexico Health Sciences Center, Albuquerque, NM 87131, USA, 5National Center for Advancing Translational Science, 9800 Medical Center Drive, Rockville, MD 20850, USA, 6Department of Computer Science, University of New Mexico, Albuquerque, NM 87131, USA, 7Department of Pharmaceutical Sciences, School of Pharmacy, The University of Texas at El Paso, TX 79902, USA, 8Computational and Structural Chemistry, Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, NJ 07033, USA, 9Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy at University of Gothenburg, 40530 Gothenburg, Sweden and 10Novo Nordisk Foundation Center for Protein Research, Faculty of Health and Medical Sciences, University of Copenhagen, 2200 Copenhagen, Denmark

ABSTRACT

DrugCentral is a public resource (http://drugcentral.org) that serves the scientific community by providing up-to-date drug information, as described in previous papers. The current release includes 109 newly approved (October 2018 through March 2020) active pharmaceutical ingredients in the US, Europe, Japan and other countries; and two molecular entities (e.g. mefuparib) of interest for COVID19. New additions include a set of pharmacokinetic properties for ~1000 drugs, and a sex-based separation of side effects, processed from FAERS (FDA Adverse Event Reporting System); as well as a drug repositioning prioritization scheme based on the market availability and intellectual property rights forFDA approved drugs. In the context of the COVID19 pandemic, we also incorporated REDIAL-2020, a machine learning platform that estimates anti-SARS-CoV-2 activities, as well as the ‘drugs in news’ feature offers a brief enumeration of the most interesting drugs at the present moment. The full database dump and data files are available for download from the DrugCentral web portal.

INTRODUCTION

DrugCentral integrates a broad spectrum of drug resources related to chemical structures, biological activities, regulatory data, pharmacology and drug formulations (1). Since 2018, DrugCentral has continuously strengthened its role as a key resource for the worldwide scientific community being additionally cross-referenced by several resources, such as UniProt (2), ChEBI (3), Hetionet (4), GUILDify (5), UniChem (6) and Guide to Pharmacology (7). DrugCentral served as primary resource for RepoDB, a drug repurposing database (8), a time-resolved computational drug repurposing algorithm (9), and an adverse drug event network for computational toxicology predictions (10). First introduced and published in the 2017 NAR database issue (1), DrugCentral reconciles the basic scientist’s understanding of the ‘drug’ concept (active pharmaceutical ingredient) with the view of the patient and healthcare practitioner (pharmaceutical formulation). Since its initial launch, the two DrugCentral papers (1,11) were cited more than 160 times cf. Google Scholar, and the website is accessed on average by ~8000 visitors monthly, with a monthly average of ~20 000 page views and over 20 000 full database downloads per year (as of 15 September 2020). Throughout regulatory and scientific documents, several terms are often used interchangeably: drug substance, new chemical (or molecular) entity and active (pharmaceutical) ingredient. While these terms have precise contextual meaning, in this paper preference

To whom correspondence should be addressed. Tel: +1 505 925 7529; Fax: +1 505 925 7625; Email: toprea@salud.unm.edu

†The authors wish it to be known that, in their opinion, the first two authors should be regarded as Joint First Authors.

© The Author(s) 2020. Published by Oxford University Press on behalf of Nucleic Acids Research.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
is given to the term ‘drug’ as synonymous with these three concepts. The term ‘formulation’ is used when discussing pharmaceutical products.

The current update adds newly approved drugs by the US Food and Drug Administration (FDA, https://www.fda.gov/home) and the European Medicines Agency (EMA, https://www.ema.europa.eu/en) up to 31 March 2020. Drugs approved by Japan Pharmaceuticals and Medical Devices Agency (PMDA, https://www.pmda.go.jp/english/index.html) were also monitored up to the latest information available, i.e. November 2019. In addition, for numerous drugs present in DrugCentral since 2018, regulatory agency information was added according to their approval status.

An important component of drug discovery and repositioning is information related to the pharmacokinetic (PK) properties of drugs, e.g. maximum recommended dose or half-life, as well as information related to side effects. In this regard, DrugCentral 2021 introduces critically reviewed information on PK, thus increasing the clinical pharmacology-related information coverage for drugs. Furthermore, adverse drug events separated by sex are tabulated at the drug level, to increase our understanding of drug safety.

Sudden outbreaks can rapidly impact global health, as evidenced by the COVID-19 pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This pandemic has accelerated the need to rely on computational platforms (12) capable of identifying and advancing novel therapeutics for clinical evaluation. In this regard, the current DrugCentral update enables computational and medicinal chemists with (i) drug repositioning categories, i.e. an in-depth classification of drugs based on current market status and intellectual property rights in the US (13), to prioritize new therapeutic uses for ‘old drugs’; and (ii) a suite of machine learning models that predict anti-SARS-CoV-2 activities, REDIAL-2020 (14), to prioritize compounds against COVID-19.

CURRENT CONTENT

Active pharmaceutical ingredients

The current DrugCentral update includes 109 newly approved drugs and two molecules (mefuparib and EIDD-2801, or ) with anti-SARS-CoV-2 potential to the 4531 indexed in 2018 (11). The vast majority of these were approved by the US FDA (95 drugs), followed by EMA (36 drugs), with 31 overlapping drugs. Compared to the additions in 2018, the number of newly approved drugs in Japan has nearly tripled, i.e. 16 new drugs compared to 6. In the past two years, the ratio of newly approved drugs between small organic molecules and biologics has changed in favor of the first class (70 small molecule drugs compared to 35 biologics), which contrasts with a more balanced ratio encountered in the last version of the database (11). Compared to the 2018 update, we note increases in the number of approved subtypes of biologics, such as antibody-drug conjugates (60% increase), oligonucleotides (50% increase) and monoclonal antibodies (30% increase). Approximately, half of the drugs processed (i.e. 52) are orphan drugs (15) pointing out the therapeutic gain in the group of rare diseases (15,16). Out of the newly added drugs, the ChEMBL database (17) indexes 104 (91) of the 111 drugs. KEGG (18) indexes 107, DrugBank captures 105 and the Guide to Pharmacology 77 drugs, respectively (Table 1).

Bioactivity data and mechanism of action

The present release adds 1379 new bioactivity datapoints from ChEMBL (17) and the Guide to Pharmacology (7) using automated pipelines, 79% and 8%, respectively; and manually curated scientific literature and approved drug label data (13%). Newly introduced drugs are associated with 551 bioactivity points from ChEMBL (65.5%), manual curation from literature (24.14%), the Guide to Pharmacology (6.17%) and approved drug labels (4.17%), respectively; as well as 109 mechanism of action (MoA or Tclin proteins—vide infra) targets, with kinases (26%) and enzymes (21%) representing the major target categories, followed by G-protein-coupled receptors—GPCRs (17%) and tumor-associated antigens (9%). Since 2018, 46 novel MoA targets, associated with 32 newly approved drugs, have been introduced (Table 2).

Our knowledge-based protein classification (19) bins human proteins into four categories, according to their ‘target development level’ (TDL): Tclin are MoA-designated drug targets via which approved drugs act (15,20,21), currently 659 human proteins; Tchem are proteins that are not Tclin, but are known to bind small molecules with high potency; Tbio includes proteins that have Gene Ontology (22) ‘leaf’ (lowest level) term annotations based on experimental evidence; or meet two of the following three conditions: A fractional publication count (23) above five, three or more Gene RIF, ‘Reference Into Function’ annotations (https://www.ncbi.nlm.nih.gov/gene/about-generif), or 50 or more commercial antibodies, as counted in the Antibodypedia portal (24). The fourth category, Tdark, currently includes ~31% of the human proteome that were manually curated at the primary sequence level in UniProt, but do not meet any of the Tclin, Tchem or Tbio criteria. DrugCentral 2021 contains 669 Tchem, 219 Tbio and 14 Tdark proteins linked to 3859, 607 and 39 bioactivity points, respectively. These proteins are mapped onto the Target Central Resource Database (TCRD) and interfaced with the TCRD portal, Pharos, respectively (25,26).

Pharmacological classification

New and existing drugs in DrugCentral were mapped (or remapped) into the latest versions of the World Health Organization Anatomic, Therapeutic and Chemical classification system (WHO ATC, https://www.whocc.no/), the FDA Established Pharmacologic Class (EPC, https://bit.ly/2OWiJdH), the Medical Subject Headings (MeSH) (27) and ChEBI (3) pharmacological classifications using the adaptive mapping schemes described in 2018. The resulting pharmacological additions are described in Table 1. Among novel drugs, 78 were linked to 136 pharmacologic classifications; 313 of the drugs were mapped to 424 additional pharmacologic terms.
Table 1. Differences in data content between DrugCentral 2016 (first release), 2018 and 2021 (current release)

| Entities (annotated drugs, or active pharmaceutical ingredients) | DrugCentral 2016 | DrugCentral 2018 | DrugCentral 2021 |
|---|---|---|---|
| **Active pharmaceutical ingredients** | 4444 | 4531 | 4642 |
| FDA drugs | 2021 | 2094 | 2220 |
| EMA drugs | 239 | 272 | 354 |
| PMDA drugs | 80 | 86 | 167 |
| Small molecules | 3799 | 3825 | 3876 |
| Biologies and peptides | 239 | 282 | 315 |
| Other drugs | 294 | 309 | 395 |
| Parent molecules | 199 (308) | 211 (327) | 216 (332) |
| **Drug efficacy targets** | | | |
| Human protein targets | 837 (1689) | 855 (1756) | 872 (1760) |
| Infectious agents targets | 600 (1387) | 613 (1447) | 659 (1534) |
| Protein–drug crystal complex (PDB) | 194 (221) | 197 (224) | 212 (230) |
| All protein–drug crystal complex (PDB) | 48 (82) | 333 (139) | 411 (165) |
| Bioactivity data points | 837 (1689) | 855 (1756) | 872 (1760) |
| Human proteins | 10 427 (1605) | 11 241 (1692) | 12 373 (1837) |
| Other species | 3398 (1002) | 4240 (1175) | 4470 (1235) |
| **Pharmacological classification** | | | |
| WHO ATC code | | | |
| FDA Established Pharmacologic Class | 4195 (2941) | 4889 (2978) | 5067 (3082) |
| MeSH pharmacological action | 428 (1165) | 450 (1220) | 462 (1256) |
| ChEBI ontology roles | 424 (2529) | 457 (2615) | 447 (2661) |
| **Drug indications** | | | |
| Drug contra-indications | 2224 (2247) | 2167 (2371) | 2241 (2496) |
| Drug off-label uses | 1458 (1376) | 1407 (1379) | 1415 (1399) |
| Rx pharmaceutical products | 847 (646) | 817 (641) | 818 (654) |
| Pharmaceutical products | 67 064 (1660) | 77 484 (1716) | 108 035 (1810) |
| OTC pharmaceutical products | 29 665 (1561) | 34 192 (1609) | 56 515 (1697) |
| External identifiers | 37 399 (286) | 43 292 (296) | 51 520 (319) |
| CAS registry number | 61 349 (4444) | 69 516 (4531) | 63 658 (4642) |
| PubChem Compound Id | 6072 (4444) | 6200 (4531) | 6350 (4642) |
| FD Unique Ingredient Identifier (UNII) | 4289 (4308) | 4399 (4412) | 462 (1256) |
| ChEMBL-db id | 4304 (4304) | 4391 (4391) | 4505 (4505) |
| WHO INN id | 4175 (4175) | 450 (1220) | 462 (1256) |
| SNOMED-CT | 4252 (2529) | 457 (2615) | 447 (2661) |
| KEKG DRUG | 285 (1487) | 295 (1529) | 303 (1607) |
| NDFRT | 239 (1165) | 272 (1447) | 222 (1654) |
| RxNorm RxCUI | 194 (221) | 197 (224) | 212 (230) |
| UPHAR/BPS ligand id | 4289 (4308) | 4399 (4412) | 462 (1256) |
| CHEBI | 1458 (1376) | 1407 (1379) | 1415 (1399) |
| MeSH | 847 (646) | 817 (641) | 818 (654) |
| Protein Databank ligand id | 67 064 (1660) | 77 484 (1716) | 108 035 (1810) |
| Protein Databank ligand id | 29 665 (1561) | 34 192 (1609) | 56 515 (1697) |
| IUPHAR | 37 399 (286) | 43 292 (296) | 51 520 (319) |
| UMLS CUI | 61 349 (4444) | 69 516 (4531) | 63 658 (4642) |
| CHEBI | 6072 (4444) | 6200 (4531) | 6350 (4642) |
| MeSH | 4289 (4308) | 4399 (4412) | 4505 (4505) |
| DrugBank | 4304 (4304) | 4391 (4391) | 4505 (4505) |
| Protein Databank ligand id | 4304 (4304) | 4391 (4391) | 4505 (4505) |
| **Pharmaceutical formulations** | | | |
| FDA pharmaceutical formulations were assessed using DailyMed data, downloaded on 9 May 2020. A total of 31 731 new formulations with effective dates starting from 30 June 2018 were added to DrugCentral 2021. The vast majority of these products (82%) are for oral (17 052) and topical (9832) administrations. The percentage of human prescription (Rx) products (52.7%) remains only slightly higher compared to OTCs. | | |

**NEW DATA AND FUNCTIONALITY**

**Drug repurposing categories**

The current version of DrugCentral includes a recently published drug repurposing categorization scheme (13), according to which drugs are sorted based on their market availability and intellectual property rights (including exclusivity protections) into three distinct categories: OFP, off-patent, which are on-market drugs with expired patents or exclusivities; ONP, on-patent, which are on-market drugs covered by current patents and exclusivity protections; and OFM, or off-market, which includes all previously marketed drugs that have been discontinued or withdrawn, respectively. The analysis, based on the US FDA’s Orange Book (FDA-OB), mapped small organic molecules and peptides from DrugCentral (having molecular weight between 100 and 1250) onto FDA-OB. In total, 996 drugs were categorized as OFP, 320 as OFM and 237 as ONP (Figure 1), respectively. These drugs can be found in a variety of pharmaceutical formulations, but oral drugs appear to be predominant in all three sets: 73% in OFP, 82% in ONP and 62% in OFM. Moreover, the data shows an increasing proportion of oral drugs in more recently approved drugs (i.e. ONP and OFP compared to OFM).

This classification scheme allows researchers to inform their decisions with respect to drug repositioning based on the existing intellectual property landscape. Given that, in time, novel drugs will be added and other drugs will change categories (i.e. ONP drugs naturally migrate to OFP and,
| Active Ingredient(s) | Target | Target Class | Agency | Indication |
|---------------------|--------|--------------|--------|------------|
| crizanlizumab       | SELP   | Adhesion     | FDA    | Vaso-occlusive crisis in sickle cell disease |
| luspatercept        | GDF11, MSTN | Cytokine | FDA    | Beta thalassemia |
| emapalumab          | IFNG   | Cytokine     | FDA    | Primary hemophagocytic lymphohistiocytosis |
| prabotulinumtoxinA  | SNAP25 | Cytosolic other | FDA | Rhytidectomy of glabellar frown lines |
| botulinum toxin type A | SNAP25 | Cytosolic other | EMA | Rhytidectomy of glabellar frown lines |
| andexanet alfa      | rivaroxaban, apixaban | Drug | FDA, EMA | Direct-acting anticoagulant adverse reaction |
| roxadustat          | EGLN1, EGLN2, EGLN3 | Enzyme | PMDA | Anemia in chronic kidney disease, refractory anemia |
| ivosidenib          | IDH1   | Enzyme       | FDA    | Acute myeloid leukemia |
| romosozumab         | SOST   | Glycoprotein  | FDA    | Postmenopausal osteoporosis |
| fremenezumab        | CALCA  | GPCR         | FDA, EMA | Migraine |
| galcanezumab        | CALCA  | GPCR         | FDA    | Migraine |
| erenumab            | CALCRL | GPCR         | FDA    | Migraine |
| ubrogepant          | CALCRL | GPCR         | FDA    | Migraine |
| romosozumab         | SOST   | Glycoprotein  | EMA    | Lennox-Gastaut syndrome, severe myoclonic epilepsy in infancy |
| branelanotide       | MC4R   | GPCR         | FDA    | Lack or loss of sexual desire |
| larotrectinib       | NTRK2, NTRK3 | Kinase | FDA, EMA | Malignant neoplasm |
| entrectinib         | NTRK2, NTRK3, ROS1 | Kinase | FDA, PMDA | Reactive oxygen species 1 positive non-small cell lung cancer, solid neoplasm with neurotrophic receptor tyrosine kinase gene fusion |
| duvelisib           | PIK3CG | Kinase       | FDA    | Chronic lymphoid leukemia, malignant lymphoma - small lymphocytic, follicular non-Hodgkin's lymphoma |
| lorlatinib          | ROS1, LTK, FER, FES, NTRK2, NTRK3, PTK2, PTK2B, TNK2 | Kinase | FDA, EMA, PMDA | Non-small cell lung cancer lung cancer |
| fostamatinib        | SYK    | Kinase       | FDA, EMA | Immune thrombocytopenia |
| ibalumab            | CD4    | Membrane receptor | FDA, EMA | Human immunodeficiency virus infection |
| tagraxofusp         | IL3RA  | Membrane receptor | FDA | Blastic plasmacytoid dendritic cell neoplasm |
| selenexor           | XPO1   | Nuclear other | FDA    | Relapse multiple myeloma |
| givosiran           | ALAS1  | RNA          | FDA, EMA | Hepatic porphyria |
| volanesorsen        | APOC3  | RNA          | EMA    | Chylomicronemia syndrome |
| golodirsen          | DMD    | RNA          | FDA    | Duchenne muscular dystrophy |
| burosomub           | FGF23  | Secreted     | FDA, EMA, PMDA | Familial x-linked hypophosphatemic vitamin D refractory rickets |
| voxelotor           | HBA1   | Transporter  | FDA    | Sickle cell disease |
| sotagliflozin       | SLC5A1 | Transporter  | EMA    | Diabetes mellitus type 1 |
| tenapanor           | SLC9A3 | Transporter  | FDA    | Irritable bowel syndrome characterized by constipation |
| polatuzumab vedotin | CD79B  | Tumor-associated antigen | FDA, EMA | Diffuse large B-cell lymphoma refractory |
| enfortumab vedotin  | NECTIN4 | Tumor-associated antigen | FDA | Metastatic urothelial carcinoma |
| caplacizumab        | VWF    | Unclassified | EMA, FDA | Thrombotic thrombocytopenic purpura |

*Selp, P-selectin; GDF11, Growth/differentiation factor 11; MSTM, Growth/differentiation factor 8; IFNG, Interferon gamma; SNAP25, Synaptosomal-associated protein 25; EGLN1, Egl nine homolog 1; EGLN2, Egl nine homolog 2; EGLN3, Egl nine homolog 3; IDH1, Isocitrate dehydrogenase [NADP] cytoplasmic; SOST, Sclerostin; CALCA, Calcitonin-gene-related peptide 1; CALCRL, Calcitonin-gene-related receptor; HTR1F, 5-hydroxytryptamine receptor 1F; GPR55, G-protein coupled receptor 55; MC4R, Melanocortin receptor 4; NTRK2, BDNF/NTR-3 growth factors receptor; NTRK3, NT-3 growth factor receptor; ROS1, Proto-oncogene tyrosine-protein kinase ROS; PIK3CG, Phosphatidylinositol 3,4,5-trisphosphate 3-kinase catalytic subunit gamma isoform; LTK, Leukocyte tyrosine kinase receptor; FER, Tyrosine-protein kinase Fer; FES, Tyrosine-protein kinase Fes; PTK2, Focal adhesion kinase 1; PTK2B, Protein-tyrosine kinase 2-beta; TNK2, Activated CDC42 kinase 1; SYK, Tyrosine-protein kinase SYK; CD4, T-cell surface glycoprotein CD4; IL3RA, Interleukin-3 receptor; XPO1, Exportin-1; ALAS1, Aminolevulinate synthase 1 (ALAS1) mRNA; APOC3, Apolipoprotein C-III (apoC-III) mRNA; DMD, exon 53 of dystrophin pre-mRNA; FGF23, Fibroblast growth factor 23; HBA1, Hemoglobin subunit alpha; SLC5A1, Sodium/glucose cotransporter 1; SLC9A3, Sodium/hydrogen exchanger 3; CD79B, B-cell antigen receptor complex-associated protein beta chain; NECTIN4, Nectin-4; VWF, von Willebrand factor;
possibly, to OFM), this drug repositioning classification will be updated on a yearly basis following the previously described workflow (13). This feature complements the pharmacopeic nature of DrugCentral, providing the scientific community (academia and industry) support to more efficiently advance ‘old’ drugs toward new therapeutic opportunities (28).

ADMET-PK data

DrugCentral 2021 now includes nine measured properties that describe pharmacokinetics (PK) such as absorption, distribution, metabolism, excretion and toxicity (ADMET) for a number of drugs. These ADMET-PK data were retrieved from five authoritative references (29–33), which themselves are extensively curated compilations from biomedical literature or drug records. These ADMET-PK properties are highly relevant for understanding the fate of drugs in the human body, for estimating dosage regimens and for conducting data analyses or machine learning studies. The number of drugs indexed with each property is summarized in Figure 2. What follows is a brief description of the ADMET-PK properties incorporated in DrugCentral 2021.

i. The absolute oral bioavailability (BA) indicates the fraction of the orally dosed drug that is absorbed through the gut, undergoes first-pass metabolism (gut and liver) and reaches systemic circulation.

ii. The volume of distribution at steady state (Vd) is the theoretical volume (expressed in L/kg) necessary to contain the measured steady-state drug concentration in plasma.

iii. The systemic (or total) clearance (CL) is the volume of plasma from which a drug is completely removed from the body. It is expressed as mL/min/kg and it is the sum of the clearance of the drug by each organ: kidneys, liver, etc.

iv. Half-life (t1/2) is the time (expressed in hours) it takes for a drug to decrease to half of its maximum concentration in plasma.

v. The fraction unbound (fu) is the fraction of drug that is not bound to plasma proteins.

vi. Water solubility (S) indicates the degree of a drug dissolving in water at neutral pH and 37°C.

vii. The extent of metabolism (EoM) is the fraction of the drug (API) excreted unchanged (mainly, in urine).

viii. The Biopharmaceutical Drug Disposition Classification System (BDDCS) is an adaptation of the FDA Biopharmaceutical Classification System for bioequivalence studies. In BDDCS, drugs are assigned to four categories in accordance with solubility and EoM cutoffs: Class 1 are high solubility, extensively metabolized drugs; Class 2 are low solubility, extensively metabolized drugs; Class 3 are high solubility, poorly metabolized drugs; and Class 4 are low solubility, poorly metabolized drugs, respectively. It should be noted that the solubility used for BDDCS is the one defined by

Figure 1. Bar plot showing the number of DrugCentral active pharmaceutical ingredients—drugs (formulated for oral versus non-oral route administration) mapped to FDA-OB and labeled as: OFP (on-market but off-patent), OFM (off-market) and ONP (on-market, on-patent), respectively (13).
FDA guidance: the solubility of the formulated active ingredient at its highest approved dose strength, in 250 mL of water, at 37°C, over the pH range 1–6.8 (https://www.fda.gov/media/70963/download). BDDCS has proven to be useful in understanding the role of drug transporters (34), in predicting the brain permeability of drugs (35) and in understanding the PK specificity of drug targets (36). BDDCS, S and EoM data gathered from two separate publications (31,32).

ix. The Maximum Recommended Therapeutic Daily Dose (MRTD) is the dose threshold above which a drug starts to manifest adverse reactions. Therefore, it is a measure of the toxicity potential of a drug. While the original publication (33) reported MRTD in mg/kg/day units, whereas DrugCentral 2021 uses μM/kg/day (i.e. the mg quantities were divided by the molecular weight of the specific active ingredient). MRTD values were re-normalized to an average body weight of 70 kg instead of the original 60 kg, although the ‘average 70 kg man’ concept needs re-evaluation (37).

As new data points become available, these will be added in DrugCentral.

**Sex-differences in adverse drug events**

FAERS (FDA Adverse Event Reporting System, https://open.fda.gov/data/faers/) data were first incorporated in DrugCentral 2018 (11). Compared to the 2018 release, there was a 10% increase in unique drugs (from 2023 to 2220), which are associated with 12,098 unique MedDRA terms (i.e. adverse events—AEs; Medical Dictionary for Regulatory Activities, https://www.meddra.org/), resulting in 739 990 drug-AE combinations. The larger the log likelihood ratio LLR value (38) for an AE, the more likely the event occurred due to a drug, and significant signals can be encountered for AEs with LLRs larger than the calculated drug-specific threshold values (t). Statistically relevant signals for the LLR test yield 1618 unique drugs associated with 8185 unique AEs, for a total of 147 191 (20%) significant drug-AE combinations. The DrugCentral 2021 FAERS dataset supports sex-specific granularity for AEs. An overview of the sex differences described in Table 3 shows a larger number of AEs reported for women compared to men. Indeed, at LLR > 5*t, the number of API-AE pairs almost doubles in females. This phenomenon, first reported in the US using FAERS data (39), and independently confirmed in the Netherlands (40), shows that sex bias in medical treatment persists, ten years after it was first discussed (41). Creating an interface that highlights sex-differences in AEs may facilitate further analyses and may reveal essential drug actions to pave the way for truly personalized medicine (42).

**REDIAL-2020**

DrugCentral 2021 incorporates a web server named ‘REDIAL-2020’ to efficiently estimate anti-SARS-CoV-2 activities from molecular structure (14). REDIAL-2020 hosts a suite of machine learning (ML) models that represent various experimental assays related to live virus infectivity (LVI), viral entry (VE) and virus replication (VR)
### Table 3. Summary of sex-specific adverse event data from FAERS, at different LLR levels

| Categories | Number of API-AE pairs (unique drugs/unique AEs) |
|------------|-----------------------------------------------|
|            | MALE                                           | FEMALE                                      |
| LLR > 0    | 403,993 (1824/9160)                           | 467,048 (1.936/9872)                        |
| LLR > 2 t  | 31,740 (968/3316)                             | 50,282 (1124/4163)                         |
| LLR > 5 t  | 12,014 (737/1735)                             | 20,845 (866/2397)                          |

AE: adverse event; LLR: log likelihood ratio; t, LLR threshold.

---

**Figure 3.** Front-page of the Drugcentral 2021 portal, featuring remdesivir in the chemical structure window.

---

process. It currently consists of six ML models that represent six assays using data from the NCATS (National Center for Advancing Translational Sciences) COVID19 portal (43). These assays are: the SARS-CoV-2 cytopathic effect, CPE (LVI) (44); Vero E6 host cell cytotoxicity (LVI counterscreen); Spike-ACE2 protein-protein interaction (AlphaLISA; VE) (45), TruHit (VE) counterscreen; angiotensin-converting enzyme 2 (ACE2; VE) inhibition; and 3C-like proteinase (3CL or Mpro; VR) inhibition (46). These models use chemical structures (or drug names; or PubChem CIDs) as input; a similarity search retrieves similar compounds in the NCATS dataset, and sorts them according to the Tanimoto similarity score. In addition to anti-SARS-CoV-2 activities, the top 10 most similar entries compared to the query molecule are displayed. Promising compounds are the ones that are (i) active in the CPE but inactive in cytotoxicity LVI models; (ii) active in the Spike-ACE2 (AlphaLISA) model and inactive in both the TruHit and ACE2 counterscreen VE models; or (iii) active in 3CL (VR) model; or any combination of the above. We are committed to update the current models periodically and build additional models to represent more assays as new data gets available in the literature.

Initially for each assay type, ML models based on each descriptor category (fingerprint, pharmacophore and physicochemical) were developed by employing 22 different ML algorithms from `scikit-learn` (47). The best performing model from each descriptor type was used to build consen-
sus models. Finally, the best performing models according to their performance on the validation and test sets (15% of the initial set, each) were picked and implemented in the REDIAL-2020 prediction server. Against three different external sets, these models exhibited predictivity in the range of 60–75%. An in-depth discussion of the models, their training procedures, performance, external predictivity and implementation are discussed elsewhere (14). Based on the same concept as the L1000 gene perturbation profile similarity, which was implemented in DrugCentral 2018 (11), REDIAL-2020 serves a complementary need, i.e. the search for drugs effective against COVID-19, as opposed to the evidence-based (factual) DrugCentral system. Both aim to support the process of drug discovery and repositioning.

**Drugs in the news**

Given the lack of approved therapeutic options, the COVID-19 pandemic has heightened the interest in approved medicines that are suitable for drug repositioning. A number of them have been used off-label in COVID-19 patients, and are therefore of interest to the community at large. Assessment of evidence for COVID-19-related treatments are frequently updated by the American Society of Health-System Pharmacists, AHSP (https://bit.ly/3mvXCQX). Reflecting heightened interest in COVID-19, the front-page of DrugCentral 2021 now includes a list of drugs that are ‘in the news’ (Figure 3). The current list includes favipiravir, which is not available in the US, but approved as Avigan in Japan and Russia and emergency approved in Italy (48) and remdesivir, which was granted emergency authorization in Japan and was FDA-approved as Veklury (https://bit.ly/33zA8Su), among other drugs.

**SUMMARY AND FUTURE DIRECTIONS**

DrugCentral 2021 is up-to-date with drug marketing approvals and patent/exclusivity annotations up to 31 March 2020 and 23 June 2020, respectively. We incorporated ADMET-PK data and sex-based adverse events from FAERS, in addition to an anti-SARS-CoV-2 activities prediction server. At its core, DrugCentral continues to index ‘pharmaceutical formulation—drug—drug target—disease’ association, although a significant number of additional attributes have been added to facilitate drug discovery and repositioning. We will continue to incorporate new drugs as soon as regulatory approvals are published. Drugs withdrawn due to other than safety reasons will be flagged in the OFM category, and all other drugs will be annually updated with respect to their marketing/patent/exclusivity status (13) in order to maintain easily accessible lists for drug repositioning. The FAERS interface will be streamlined to highlight sex differences in the drug safety profiles of existing drugs. Within the next six months, we plan to launch a chemical substructure and similarity search functionality. Last but not least, we have performed an extensive curation of veterinary drugs, which will be annotated in the next major DrugCentral release.

**DATA ACCESS**

**Web interface**

The DrugCentral web interface has been updated since the 2018 release to integrate novel data types and functionalities. The ‘Drugs in the news’ section will be updated monthly, by monitoring drugs that are widely associated with current events.

**Download**

DrugCentral data can be downloaded in PostgreSQL format (full database dump available) for advanced data query, export and integration. User interaction with the local instance is facilitated through structured query language (SQL) examples as previously available, together with downloads of the chemical structures of the drugs in several formats (e.g. SDF, InChI and SMILES) and drugs bioactivity profiles in tabular format. The database is available via Docker container (https://dockr.ly/35G46a6), and public instance drugcentral:unmtid-dbs.net:5433. A Python API is also available (https://bit.ly/2RAHHTV).

**SUPPLEMENTARY DATA**

Supplementary Data are available at NAR Online.

**FUNDING**

National Institutes of Health (NIH) Common Fund [U24 CA224370 to S.A., C.G.B., J.H., T.B.W., R.C., L.H., A.B., J.J.Y., J.K., T.I.O.]; NIH National Cancer Institute (NCI) Cancer Center Support Grant for UNM [P30 CA118100 to C.G.B., T.I.O.]; NIH NCATS Clinical and Translational Science Center for UNM [UL1 TR001449 to T.I.O.]; Intramural Research Program, Division of Preclinical Innovation, NIH NCATS (to D.T.N.); National Science Foundation [NSF-PREM, DMR-1827745 to S.S.]; Funding for open access charge: NIH [CA224370].

**Conflict of interest statement.** T.I.O. has received honoraria or consulted for Abbott, AstraZeneca, Chiron, Genentech, Infinity Pharmaceuticals, Merz Pharmaceuticals, Merck Darmstadt, Mitsubishi Tanabe, Novartis, Ono Pharmaceuticals, Pfizer, Roche, Sanofi and Wyeth. He is on the Scientific Advisory Board of ChemDiv Inc. and InSilico Medicine.

**REFERENCES**

1. Ursu,O., Holmes,J., Knockel,J., Bologa,C.G., Yang,J.J., Mathias,S.L., Nelson,S.J. and Oprea,T.I. (2017) DrugCentral: online drug compendium. *Nucleic Acids. Res.*, 45, D932–D939.
2. UniProtConsortium (2019) UniProt: a worldwide hub of protein knowledge. *Nucleic. Acids. Res.*, 47, D506–D515.
3. Hastings,J., Owen,G., Dekker,A., Ennis,M., Kale,N., Muthukrishnan,V., Turner,S., Swainston,N., Mendes,P. and Steinbeck,C. (2016) ChEBI in 2016: Improved services and an expanding collection of metabolites. *Nucleic. Acids. Res.*, 44, D1214–D1219.
4. Himmelstein,D.S., Lizee,A., Hessler,C., Brueggeman,L., Shen,S.L., Hadley,D., Green,A., Khanhkanian,P. and Baranzini,S.E. (2017) Systematic integration of biomedical knowledge prioritizes drugs for repurposing. *Elife*, 6, e26726.
5. Aguirre-Plans,J., Pujero,J., Sanz,F., Furlong,L.I., Fernandez-Fuentes,N., Oliva,B. and Guneye,E. (2019) GUILDify v2.0: A tool to identify molecular networks underlying human diseases, their comorbidities and their druggable targets. *J. Mol. Biol.*, 431, 2477–2484.

6. Chambers,J., Davies,M., Gaulton,A., Hersey,A., Velankar,S., Petryszak,R., Hastings,J., Bellis,L., McGlinchey,S. and Overington,J.P. (2013) UniChemin: a unified chemical structure cross-referencing and identifier tracking system. *J. Cheminform.*, 5, 3.

7. Alexander,S.P.H., Kelly,E., Mathie,A., Peters,J.A., Veale,E.L., Armstrong,J.F., Facenda,E., Harding,S.D., Pawson,A.J., Sharman,J.L. et al. (2019) The concise guide to pharmacology 2019: Introduction and other protein targets. *Br. J. Pharmacol.*, 176, S1–S20.

8. Brown,A.S. and Patel,C.J. (2017) A standard database for drug repositioning. *Scientific Data*, 4, 170029.

9. Mayer,S.M., Li,T.S., Queralt-Rosinach,N. and Su,A.I. (2019) Development of an off-patent drug repositioning targets in 2019. *Sci.Rep.*, 9, 111–111.

10. Wu,Q., Taboureau,O. and Audouze,K. (2020) Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose. *Regul. Toxicol. Pharmacol.*, 40, 185–206.

11. Shugarts,S. and Benet,L.Z. (2009) The role of transporters in the pharmacokinetics of orally administered drugs. *Pharm. Res.*, 26, 2039–2054.

12. Broccatelli,F., Larregieu,C.A., Cruciani,G., Opiea,T.I. and Benet,L.Z. (2012) Improving the prediction of the brain disposition for orally administered drugs using BDDCS. *Adv. Drug Deliv. Rev.*, 64, 93–109.

13. Bocci,G., Benet,L.Z. and Opiea,T.I. (2019) Can BDDCS illuminate drug design? *Drug Discov. Today*, 24, 2299–2306.

14. Ashar,B.H. (2018) In search of the 70-kg man. *Med. Clin. North Am.*, 102, xv–xvi.

15. Huang,L., Zalkikar,J. and Tiwari,R.C. (2011) A likelihood ratio test based method for signal detection with application to FDA’s drug safety data. *J. Am. Stat. Assoc.*, 106, 1230–1241.

16. Yu,Y., Chen,J., Li,D., Wang,L., Wang,W. and Liu,H. (2016) Systematic analysis of adverse event reports for sex differences in adverse drug events. *Sci. Rep.*, 6, 24955.

17. de Vries,S.T., Denig,E., Ekhart,C., Burgers,J.S., Kleefstra,N., Mol,P.G.M. and van Puikenbroek,E.P. (2019) Sex differences in adverse drug reactions reported to the National Pharmacovigilance Centre in the Netherlands: An exploratory observational study. *Br. J. Clin. Pharmacol.*, 85, 1507–1515.

18. Kim,A.M., Tingen,C.M. and Woodruff,T.K. (2010) Sex bias in trials and treatment must end. *Nature*, 465, 688–689.

19. Opiea,T.I. (2019) Exploring the dark genome: implications for precision medicine. *Mamm. Genome*, 30, 192–200.

20. Brimacombe,K.R., Zhao,T., Eastman,R.T., Hu,X., Wang,K., Backus,M., Baljinnyam,B., Chen,C.Z., Chen,L., Eicher,T. et al. (2020) An OpenData portal to share COVID-19 drug repurposing data in real time. bioRxiv doi: https://doi.org/10.1101/2020.06.04.135046, 05 June 2020, preprint: not peer reviewed.

21. Chen,C.Z., Shinn,P., Itkin,Z., Eastman,R.T., Bologa,C.G., Jensen,L.J., Vidovic,D., Koleti,A., Schirr,S.C. et al. (2021) TCRD and Pharos 2021: Mining the human proteome for disease biology. *Nucleic Acids Res.*, 49, D995–D1002.

22. Sheils,T.K., Mathias,S.L., Kelleher,K.J., Siramshetty,V.B., Nguyen,D.-T., Bologa,C.G., Jensen,L.J., Vidovic,D., Koleti,A., Schirr,S.C. et al. (2021) TC RD and Pharos 2021: Mining the human proteome for disease biology. *Nucleic Acids Res.*, 49, D995–D1002.

23. Nelson,S.J. (2009) Medical terminologies that work: The example of MeSH. In: 2009 10th International Symposium on Pervasive Systems, Algorithms, and Networks., pp. 380–384.

24. Opiea,T.I. and Overington,J.P. (2015) Computational and practical aspects of drug repositioning. *Assay Drug Dev. Technol.*, 13, 299–306.

25. Bologa,C.G., Karlsson,A., Al-Lazikani,B., Hersey,A., Oprea,T.I. et al. (2017) A comprehensive map of molecular drug targets. *Nat. Rev. Drug Discov.*, 16, 192–200.

26. Benson,D.A., Karsch-Mizrachi,I., Lipman,D.J., Ostell,J. and Wheeler,D.L. (2010) GenBank. *Nucleic Acids Res.*, 38, D16–D19.

27. Nelson,S.J. (2009) Medical terminologies that work: The example of MeSH. In: 2009 10th International Symposium on Pervasive Systems, Algorithms, and Networks., pp. 380–384.

28. Oprea,T.I. and Overington,J.P. (2015) Computational and practical aspects of drug repositioning. *Assay Drug Dev. Technol.*, 13, 299–306.

29. Benet,L.Z., Broccatelli,F. and Opiea,T.I. (2011) BDDCS applied to over 900 drugs. *AAPS J.*, 13, 519–547.

30. Husey,C.M., Chan,R. and Benet,L.Z. (2016) BDDCS predictions, Self-Correcting aspects of BDDCS assignments, BDDCS assignment corrections, and classification for more than 175 additional drugs. *AAPS J.*, 18, 251–260.

31. Contrera,J.F., Matthews,E.J., Krulikh,N.L. and Benz,R.D. (2004) Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose. *Regul. Toxicol. Pharmacol.*, 40, 185–206.

32. Shugarts,S. and Benet,L.Z. (2009) The role of transporters in the pharmacokinetics of orally administered drugs. *Pharm. Res.*, 26, 2039–2054.

33. Broccatelli,F., Larregieu,C.A., Cruciani,G., Opiea,T.I. and Benet,L.Z. (2012) Improving the prediction of the brain disposition for orally administered drugs using BDDCS. *Adv. Drug Deliv. Rev.*, 64, 93–109.

34. Benet,L.Z., Broccatelli,F. and Opiea,T.I. (2011) BDDCS applied to over 900 drugs. *AAPS J.*, 13, 519–547.

35. Bocci,G., Benet,L.Z. and Opiea,T.I. (2019) Can BDDCS illuminate drug design? *Drug Discov. Today*, 24, 2299–2306.

36. Ashar,B.H. (2018) In search of the 70-kg man. *Med. Clin. North Am.*, 102, xv–xvi.

37. Huang,L., Zalkikar,J. and Tiwari,R.C. (2011) A likelihood ratio test based method for signal detection with application to FDA’s drug safety data. *J. Am. Stat. Assoc.*, 106, 1230–1241.

38. Yu,Y., Chen,J., Li,D., Wang,L., Wang,W. and Liu,H. (2016) Systematic analysis of adverse event reports for sex differences in adverse drug events. *Sci. Rep.*, 6, 24955.

39. de Vries,S.T., Denig,E., Ekhart,C., Burgers,J.S., Kleefstra,N., Mol,P.G.M. and van Puikenbroek,E.P. (2019) Sex differences in adverse drug reactions reported to the National Pharmacovigilance Centre in the Netherlands: An exploratory observational study. *Br. J. Clin. Pharmacol.*, 85, 1507–1515.

40. Kim,A.M., Tingen,C.M. and Woodruff,T.K. (2010) Sex bias in trials and treatment must end. *Nature*, 465, 688–689.

41. Opiea,T.I. (2019) Exploring the dark genome: implications for precision medicine. *Mamm. Genome*, 30, 192–200.

42. Brimacombe,K.R., Zhao,T., Eastman,R.T., Hu,X., Wang,K., Backus,M., Baljinnyam,B., Chen,C.Z., Chen,L., Eicher,T. et al. (2020) An OpenData portal to share COVID-19 drug repurposing data in real time. bioRxiv doi: https://doi.org/10.1101/2020.06.04.135046, 05 June 2020, preprint: not peer reviewed.

43. Chen,C.Z., Shinn,P., Itkin,Z., Eastman,R.T., Bostwick,R., Rasmussen,L., Huang,R., Shen,M., Hu,X., Wilson,K.M. et al. (2020) Drug repurposing screen for compounds inhibiting the cytopathic effect of SARS-CoV-2. bioRxiv doi: https://doi.org/10.1101/2020.08.18.255877, 18 August 2020, preprint: not peer reviewed.

44. Chen,C.Z., Shinn,P., Itkin,Z., Eastman,R.T., Bologa,C., Jensen,L.J., Vidovic,D., Koleti,A., Schirr,S.C. et al. (2021) TC RD and Pharos 2021: Mining the human proteome for disease biology. *Nucleic Acids Res.*, 49, D995–D1002.
46. Zhu, W., Xu, M., Chen, C.Z., Guo, H., Shen, M., Hu, X., Shinn, P., Klumpp-Thomas, C., Michael, S.G. and Zheng, W. (2020) Identification of SARS-CoV-2 3CL protease inhibitors by a quantitative high-throughput screening. *ACS Pharmacol. Transl. Sci.*, 3, 1008–1016.

47. Pedregosa, F., Varoquaux, G., Gramfort, A., Michel, V., Thirion, B., Grisel, O., Blondel, M., Prettenhofer, P., Weiss, R., Dubourg, V. *et al.* (2011) Scikit-learn: Machine learning in Python. *J. Mach. Learn Res.*, 12, 2825–2830.

48. Agrawal, U., Raju, R. and Udwadia, Z.F. (2020) Favipiravir: A new and emerging antiviral option in COVID-19. *Armed Forces Med. J. India*, doi:10.1016/j.mjafi.2020.08.004.